STRATA SKIN SCIENCES INC (SSKN)
US86272A2069 - Common Stock
Taking everything into account, SSKN scores 1 out of 10 in our fundamental rating. SSKN was compared to 195 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of SSKN have multiple concerns. SSKN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SSKN had negative earnings in the past year.
In the past year SSKN has reported a negative cash flow from operations.
SSKN had negative earnings in each of the past 5 years.
In multiple years SSKN reported negative operating cash flow during the last 5 years.
1.2 Ratios
SSKN has a Return On Assets of -25.79%. This is comparable to the rest of the industry: SSKN outperforms 50.26% of its industry peers.
SSKN has a Return On Equity of -85.41%. This is in the lower half of the industry: SSKN underperforms 63.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.79% | ||
| ROE | -85.41% | ||
| ROIC | N/A |
ROA(3y)-14.07%
ROA(5y)-11.93%
ROE(3y)-40.48%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SSKN has a Gross Margin (55.35%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SSKN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SSKN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-0.7%
2. Health
2.1 Basic Checks
SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SSKN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SSKN has been increased compared to 5 years ago.
Compared to 1 year ago, SSKN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.16, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
SSKN has a worse Altman-Z score (-7.16) than 71.79% of its industry peers.
SSKN has a Debt/Equity ratio of 1.19. This is a high value indicating a heavy dependency on external financing.
SSKN has a worse Debt to Equity ratio (1.19) than 81.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.16 |
ROIC/WACCN/A
WACC11.68%
2.3 Liquidity
A Current Ratio of 1.28 indicates that SSKN should not have too much problems paying its short term obligations.
The Current ratio of SSKN (1.28) is worse than 88.21% of its industry peers.
A Quick Ratio of 1.06 indicates that SSKN should not have too much problems paying its short term obligations.
SSKN's Quick ratio of 1.06 is on the low side compared to the rest of the industry. SSKN is outperformed by 82.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
The earnings per share for SSKN have decreased strongly by -80.65% in the last year.
SSKN shows a decrease in Revenue. In the last year, the revenue decreased by -7.74%.
The Revenue has been growing slightly by 2.24% on average over the past years.
EPS 1Y (TTM)-80.65%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-2100%
Revenue 1Y (TTM)-7.74%
Revenue growth 3Y13.05%
Revenue growth 5Y2.24%
Revenue growth Q2Q-18.03%
3.2 Future
The Earnings Per Share is expected to grow by 27.90% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 0.14% on average over the next years.
EPS Next Y30.42%
EPS Next 2Y27.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.33%
Revenue Next 2Y0.14%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SSKN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SSKN's earnings are expected to grow with 27.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.9%
EPS Next 3YN/A
5. Dividend
5.1 Amount
SSKN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
STRATA SKIN SCIENCES INC
NASDAQ:SSKN (4/26/2024, 6:19:42 PM)
0.5145
-0.01 (-2.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap18.04M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.79% | ||
| ROE | -85.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.35% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.19 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-80.65%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y30.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.74%
Revenue growth 3Y13.05%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y